Introduction
Diabetes is accepted as an independent risk factor for cardiovascular events. The risk for coronary heart disease (CHD), stroke and peripheral arterial disease (PAD) is increased by a factor of two to four, as shown by the Multiple Risk Factor Intervention Trial (MRFIT). 3 Diabetic patients are therefore grouped in the same risk group as those who have survived a stroke or a myocardial infarction. [4] [5] [6] In addition to their increased risk for cardiovascular disease (CVD), patients with diabetes have a poorer prognosis than non-diabetic patients when they experience a major ischaemic vascular event. The prognosis for diabetic patients who undergo coronary revascularisation procedures is worse than that for non-diabetic subjects; patients with diabetes experience more postprocedural complications and have decreased infarct-free survival. 7, 8 As a seminal component of the so-called metabolic syndrome, insulin resistance plays a significant role in the development of vascular dysfunction. 9 An increase in the fasting insulin level predicts the development of hypertension in non-obese non-diabetic persons. [9] [10] [11] [12] Insulin resistance is associated with reduced nitric oxide-mediated vasodilatation and increased salt sensitivity. [10] [11] [12] Insulin levels are directly correlated with plasminogen activator inhibitor-1 (PAI-1) and inversely correlated with tissue plasminogen activator (tPA). 13 The fact that insulin induces PAI-1 activity both in vitro and in vivo supports the concept that hyperinsulinaemic states are pro-thrombotic. 14, 15 The metabolic syndrome is characterised by microalbuminuria, high triglycerides, low high-density lipoprotein (HDL) cholesterol, hypertension, left ventricular hypertrophy and increased platelet aggregation and coagulopathy. [10] [11] [12] The pathophysiology of diabetic micro-and macroangiopathy may depend on whether the patient has type I or II disease but both types of diabetes are associated with a hypercoaguable state driven by platelet hyperreactivity. The majority of ischaemic coronary and cerebrovascular events are characterised by vessel occlusion caused by atherosclerotic plaque disruption, platelet aggregation and adhesion which result in intravascular thrombosis. [16] [17] [18] [19] [20] [21] [22] Metabolism and classical cardiovascular risk factors are associated with vascular damage caused by disturbed interaction of platelets with the walls of small and large arteries, leading to damage of the dependent parenchymal organs (retina, kidney, heart, brain etc.). Recently Eibl and coworkers were able to show that improved metabolic control can decrease platelet activation in patients with type 2 diabetes. After three months of improved metabolic control, a significant decline of the platelet activation markers CD31, CD49b, CD62P and CD63 was noted. 23 Antiplatelet therapy has proven particular clinical efficacy for patients in primary, secondary and tertiary prevention of vascular thrombotic disease. stances (thrombin, collagen, adenosine diphosphate [ADP], epinephrine, vasopressin, serotonin, platelet activating factor) are capable of activating platelets by binding to the membrane-located receptors, resulting in a well defined outside-in signalling. These intraplatelet events lead to integrin activation ('inside-out' signalling): the constitutive integrin α IIb β 3 (glycoprotein IIb/IIIa) changes its steric conformation, exposing the high-affinity binding site for RGD (arginine-glycine-asparagine) containing ligands such as fibrinogen. This reaction results in cross-bridging of activated platelets by binding of the polyvalent ligand fibrinogen. 29 When platelets are activated they react by changing their morphology, aggregating, secreting various proteins and by liberating arachidonic acid that is rapidly converted to prostaglandins and lipoxygenase products. Constituents from α-granule stores like platelet factor-4 (PF-4) 30 and β-thromboglobulin [31] [32] [33] are released and cell surface activation markers like p-selectin, 34, 35 CD63 and CD40L [36] [37] [38] [39] are upregulated. Activated platelets show an increased adhesiveness and aggregation in response to collagen, thrombin and platelet activating factor. This may lead to increased microembolism in the capillaries and local progression of pre-existing vascular lesions. 16, 40 Abnormalities in platelet function may exacerbate the progression of atherosclerosis and the consequences of plaque rupture. The abnormal metabolic state that accompanies diabetes causes arterial dysfunction. Relevant abnormalities include chronic hyperglycaemia, dyslipidaemia and insulin resistance, which engender adverse metabolic events within the endothelial cell. Activation of these systems impairs endothelial function, augments vasoconstriction, increases inflammation and promotes thrombosis; these are the characteristics of so-called endothelial dysfunction.
In diabetes the complex regulation of platelet activity is altered towards:
• increased reactivity and adhesion 19, 41, 42 • amplified agonist-receptor coupling 43, 44 • increased capacity for prostanoid generation [45] [46] [47] • decreased capacity for nitric oxide (NO-) generation [48] [49] [50] • enhanced generation of reactive oxygen species 51, 52 • resistance to NO-and prostacyclin 53, 54 • increased cytosolic calcium mobilisation 52, 55, 56 • increased α-granule content with concomitantly increased release 57 • increased platelet volume 58 • increased numbers of glycoprotein receptors GPIb and GPIIb/IIIa 59 • increased membrane protein glycation 60 • altered membrane fluidity 61, 62 • increased binding of adhesive RGD-protein ligands (e.g. fibrinogen) 63, 64 • increased content and release of plasminogen activator inhibitor-1 65, 66 17, 18, 21 These alterations lead to a downshift of the coagulation threshold in the arterial circulation where occlusive thrombi induce hypoxic damage to parenchymal organs. [67] [68] [69] [70] On the other hand, occlusion of the capillaries by platelet or mixed platelet-leukocyte emboli may cause sustained occlusion of the functional microcirculation even without any acute clinical symptoms. Basement membrane thickening, microaneurysms and capillary occlusions have been reported and would serve as pathological substrate for the diabetic microangiopathy. NO synthase activity [48] [49] [50] O 2 -, OONO -production 51, 52 Prostacyclin synthesis 53, 54 Prostacyclin sensitivity 53, 54 Receptor for advanced glycation end products expression 60, 142 Other factors Plasma histamine 143 Plasma serotonin 143 Tumour necrosis factor-α 140 The clinical significance of platelet hyperactivity in diabetes may be derived from the Platelet Aggregation as a risk Factor in Diabetics (PARD) study, showing that the incidence of macrovascular end points in male diabetic patients was strongly related to the degree of spontaneous platelet aggregation at study entry. [73] [74] [75] Activated platelets: a proteomic approach With its numerous effects on platelet function, diabetes predisposes to atherosclerosis and thrombosis, including increased primary and secondary platelet aggregation, platelet activation with release of contents of α-granules and enhanced surface expression and activation of glycoprotein IIb/IIIa complex. 57, 59 Besides the mitogenic factors PDGF (platelet-derived growth factor), TGF-β (transforming growth factor-β), VEGF (vascular endothelial growth factor), bFGF (basic fibroblast growth factor), PDEGF (plateletderived epidermal growth factor) and IGF-1 (insulin-like growth factor-1), α-granules contain PF-4 (platelet factor-4), PAI-1 (plasminogen activator inhibitor-1), β-thromboglobulin, fibrinogen, fibronectin, thrombospondin and vWF (von Willebrand factor), which are increased in measurable amounts upon activation. 76 In diabetic patients platelets show a hypersensitivity to collagen and the elevated expression of platelet F c -receptor correlates with the increased collagen-induced aggregation. [77] [78] [79] [80] Glycoprotein VI has been identified as the major platelet collagen receptor. 81, 82 Recently, Coppinger and co-workers characterised the proteins released from activated platelets in a proteomicsbased assay and identified more than 300 proteins which were released by platelets upon activation with thrombin. 83 Of these proteins many had not been previously attributed to platelets, including secretogranin III (potential monocyte chemoattractant precursor), cyclophilin A (vascular smooth muscle cell growth factor) and calumenein (inhibitor of the vitamin K epoxide reductase-warfarin interaction). It was also confirmed that these proteins were localised in platelets and released upon activation.
Secretogranin III stimulates monocyte adhesion to the vessel wall and their transendothelial migration. 84 Cyclophilin A acts as an autocrine stimulator for extracellular signal-reduced kinase (ERK1/2) and vascular smooth muscle proliferation and is secreted by vascular smooth muscle cells in response to oxidative stress. 85 Coppinger et al. propose that cyclophilin A released from activated platelets may stimulate the migration and proliferation of smooth muscle cells, a process becoming implicated in the development of atherosclerosis. 83 Since PDGF is also a mitogen for fibroblasts and smooth muscle cells, stimulating angiogenesis and collagen production, there could be an accelerating effect if both growth factors are up-regulated. Calumenin inhibits the activity of vitamin K epoxide reductase, which converts vitamin K to its hydroquinone form, a cofactor for the enzyme γ-carboxylase, thus inhibiting γ-carboxylation. 86 Because morphogenetic protein (MGP) function requires γ-carboxylation in the aortic vessel wall, the authors speculate that warfarin treatment and calumenin deposition in atherosclerotic plaques may promote vascular calcification by blocking vitamin K-dependent γ-carboxylation and hence MGP activity. 83, 87 Therefore it is likely that platelet adhesion contributes to the development of atherosclerosis through proteins which are released from platelets upon activation.
Activated platelets: a genomic approach
As platelets are not supplied with all elements of the transcriptional apparatus, constitutive proteins have to be synthesised in megakaryocytes and packed into platelet precursors, which are afterwards shed into the peripheral circulation. [88] [89] [90] [91] Glycoprotein GPIb and GPIIb/IIIa act as specific receptors for cytoadhesive proteins. The measured amount of glycoproteins in activated platelets exceeds the expected increase with larger platelet volume. 59 Thus, there seems to be a change in the level of expression and/or synthesis. As the surface glycoproteins are megakaryocytic lineage markers, it is assumed that the change takes place at the level of megakaryocytic thrombopoiesis. Insulin influences the size and maturation status of megakaryocytes in culture, indicating a possible influence of insulin on the endomitotic cycle of megakaryocytes. 92 A study in adult genetically related Brattleboro (BB) rats, a model for immunogenic type I-like diabetes mellitus, resulted in significant qualitative and quantitative changes in platelets and megakaryocytes when simultaneous DNA and lineage-specific α IIb β 3 (CD41, GPIIa/IIIb) staining patterns were analysed. 93 These results can be explained by an enhanced recruitment of progenitor cells along with consumption of the mature higher-ploidy megakaryocytes in recent-onset diabetes. Enhanced megakaryocyte maturation together with the release of a high number of larger platelets then reflects a superimposed insulin effect, which could be mediated by various interleukins. [94] [95] [96] [97] The finding that circulating peripheral platelets are already in an activated state in newly diagnosed patients, and even in prediabetic, immunologically affected, patients suggests a chronic condition of ongoing platelet consumption. 98 The reaction of the bone marrow may be an increased release of platelets considering that the peripheral platelet count does not appear severely affected in human studies: this suggests increased turnover. 99 In summary, the observations in spontaneously diabetic BB rats and available human data suggest that there is a primary alteration in the level of bone marrow (megakaryocytic) stem cells which appears in a thrombopoietin-dependent manner. The interplay of the differential biological mediators upon the process of stem cell differentiation, clonal expansion, megakaryocyte maturation and the process of platelet formation in the diabetic state remains to be elucidated.
Functional changes in platelet proteins may rely on single nucleotide polymorphisms within the megakaryocytic genetic code. The thrombosis-associated PI-A1/PI-A2 single nucleotide polymorphism of the fibrinogen receptor integrin GPIIb/IIIa has been investigated as a candidate of such an assumption. The relative frequency of the PI A2 allele has been found to be increased in patients with diabetes but, in contrast to the non-diabetic population, this REVIEW increase appeared independent from clinical atherosclerosis. 100 This finding supports the hypothesis of a primary risk condition operating by megakaryocyte lineage stem cells and fits with the so-called common soil hypothesis of type 2 diabetes. Consistent with the concept of genetic preconditioning, a polymorphism of the platelet collagen receptor GPIa/IIa was described to be associated with the development of diabetic retinopathy. 101 As collagen is an important mediator of platelet activation, the corresponding receptors have been studied extensively. The binding of collagen to glycoprotein (GP) VI induces platelet activation through a pathway that involves phosphorylation of the FcRγ-chain followed by the binding of Syk and the phosphorylation-dependent activation of PlCγ2. [77] [78] [79] [80] The platelet integrin α IIb β 3 is activated by the binding of von Willebrand Factor (vWF) to the GPIb complex and may stimulate activation of α 2 β 1 . Three VNTR-polymorphisms are relevant to the expression and function of the GPIb α -subunit located within the mucin-like macroglycopeptide region of GPIb α . 102, 103 Another dimorphism (Met Thr 145 ) located within the region of the ligandbinding, leucin-rich motifs (LRM) is the basis of the HPA-2 platelet alloantigen system and is in linkage disequilibrium with the VNTR-polymorphism. 104, 105 Preliminary results show that the Met 145 -allele seems to be associated with the risk for coronary artery disease or stroke in young persons. A C T substitution upstream of the start codon influences an adjacent Kozak sequence and thus the rate of protein biosynthesis. The -5C allele (f=15% in the western population) increases the mean level of GPIb α on the platelet plasma membrane due to the enhancement of mRNA translation. 106, 107 An association of the -5C allele with the severity of negative outcomes after acute myocardial infarction in younger patients (< 62 years) was seen in recent studies. 108 A synergistic effect of the -5C and the Met 145 polymorphisms were detected, resulting in an increased risk for stroke in young individuals. 109 The relative level of α 2 β 1 correlates to three α 2 alleles. Allele 1 (807T/1638A/2531C, f=39%) is associated with increased levels of α 2 β 1 whereas allele 2 (807C/1638G/ 2531C, f=53%) and allele 3 (807C/1638A/2531C, f=8%) are each associated with decreased levels of this receptor. 110, 111 Individuals who are homozygous for allele 1 express on average four-fold the amount of α 2 β 1 receptor compared to persons who are homozygous for allele 2. A strong association between allele 1 and non-fatal myocardial infarction was found among patients below 62 years and an even stronger correlation was detected in younger persons (< 49 years) in the same study. 112 A significant association was also found in younger patients with stroke 113 and in patients with diabetic retinopathy. 114 In a cohort of Dutch women, individuals with 807TT genotype and at least two markers of compromised endothelial function (smoking, diabetes or microalbuminuria) have a significantly increased relative risk of cardiovascular mortality. 115 Genetic polymorphisms concerning the transcriptional regulation of the α 2 -gene are single base substitutions within the proximal 5'-regulatory region: C-52T and C-92G. 116, 117 They contribute to the regulation of integrin α 2 β 1 expression on megakaryocytes and blood platelets and therefore modulate collagen-related platelet function in vivo. The density of platelet α 2 β 1 has not been found to be a risk factor for venous thrombosis. This is a typical finding for most platelet glycoprotein dimorphisms.
Leukocyte-platelet cross-talk in diabetes
Pathophysiological processes such as inflammation or thrombosis show multicellular activation involving endothelial cells, leukocytes and platelets. The complex interactions between these cells -the cross-talk -is influenced by several mediators. Platelets may influence leukocyte activation, chemotaxis and phagocytosis. 118 Platelet-released adenine nucleotides and plateletderived growth factor (PDGF) may induce leukocyte degranulation. Adherent platelets, 119 platelet-derived microparticles, 120 and platelet-released substances, such as PDGF, platelet factor 4 and thromboxane A2 (TXA2) enhance leukocyte rolling and adhesion. Furthermore, PDGF is chemotactic and enhances phagocytosis by neutrophils and monocytes. Superoxide formation by neutrophils may be promoted by platelets bound to neutrophils 121 or platelet-released ADP whereas intact platelets may inhibit neutrophil superoxide production. Leukocyte chemotaxis, adhesion and superoxide generation are inhibited by p-selectin and NO released from platelets. 122, 123 In summary, platelets and platelet-derived products influence leukocyte function in several ways.
Leukocytes may influence platelet adhesion directly or through leukocyte-released superoxide. Platelet aggregation and secretion are induced by superoxide, platelet activating factor, metalloproteases like cathepsin G, and neutrophil elastase. Platelets and leukocytes may form plateletleukocyte aggregates or conjugates (PLAs), mainly via platelet-expressed p-selectin and its receptors p-selectin glycoprotein ligand-1 (PSGL-1) and CD15, as well as via fibrinogen bridging between glycoprotein (GP) IIb/IIIa and CD11b/CD18.
Li and co-workers were able to demonstrate plateletleukocyte cross-talk in a whole blood assay. 124 Leukocytes activated with N-formyl-methionyl-leucyl-phenylalanine (fMLP) induced platelet activation with increased expression of platelet p-selectin. The effects may be related to the generation of PAF, 5-lipoxygenase production and superoxide. Collagen-induced activation of platelets led to a significant leukocyte activation which was monitored by the expression of CD11b on leukocytes. During platelet-leukocyte cross-talk, p-selectin and GPIIb/IIIa take part in cellular signalling. 124 The complex pathological process of diabetic angiopathy involves atherosclerosis, inflammation and thrombosis, with platelet and leukocyte dysfunction playing a central role. In diabetic microangiopathy, increased platelet and leukocyte activation and heterotypic aggregation are present. 72, [125] [126] [127] [128] Leukocytes from diabetic subjects exhibit enhanced adhesion molecule expression 101 and increased aggregability. They are associated with impaired cell deformability, 129 decreased chemotaxis 130 and altered superoxide anion production. 131 
REVIEW
Platelets and leukocytes are known to interact and modulate each others' function. Platelet-leukocyte crosstalk involves both heterotypic cell-cell contact and soluble mediators released from platelets and leukocytes which may prime both platelets and leukocytes and thus enhance platelet and leukocyte reactivity. 124 Hu and co-workers evaluated platelet-leukocyte cross-talk and its contribution to platelet and leukocyte dysfunction and microangiopathy in type 1 diabetes mellitus patients. 132 Whereas basal single platelet p-selectin and leukocyte CD11b expression levels were similar in diabetic patients and healthy subjects, circulating platelet-leukocyte aggregates and the amount of plasma elastase were elevated in diabetic patients. Upon treatment with the thromboxane A 2 -analogue U46619, a remarkable increase of platelet p-selectin expression and platelet-leukocyte aggregation was detectable. The leukocyte-specific agonist N-formyl-methionyl-leucyl-phenylalanine (fMLP) induced more marked CD11b expression in patients with diabetes mellitus with microangiopathy. Platelet-leukocyte cross-talk induced by U46619 showed no difference between patients and healthy subjects. FMLP evoked marked leukocyte activation, which subsequently caused mild platelet p-selectin expression. This leukocyteplatelet cross-talk was more pronounced in patients than in healthy subjects. Enhanced leukocyte-platelet cross-talk was correlated to platelet hyperreactivity among diabetes mellitus patients with microangiopathy only.
Hu et al. found that patients with diabetes mellitus had elevated plasma levels of elastase, which can in turn induce platelet activation. Also, other soluble mediators of platelet-leukocyte cross-talk such as platelet activating factor (PAF) and the superoxide anion are enhanced in type I diabetes and could therefore act together. 132 Plateletmonocyte aggregation was observed in diabetics with microangiopathy, which may facilitate tissue factor transfer between monocytes and platelets, 133, 134 resulting in increased thrombin generation. The fact that basal pselectin levels did not differ significantly but platelet-leukocyte aggregates were distinguishable in healthy subjects and patients lead to the concept that platelet-leukocyte aggregates may be a more sensitive marker of platelet activation in vivo. Hu et al. suppose that leukocyte-platelet cross-talk may also prime platelets to be more sensitive to activation, which was demonstrated in the in vitro activation with U46619 in the case of patients with microangiopathy. 132 Type I diabetes is associated with platelet and leukocyte hyperactivity, enhanced platelet-leukocyte aggregation and enhanced leukocyte-platelet cross-talk, especially in patients with microangiopathy. The enhancement of leukocyte-platelet cross-talk may contribute to diabetic platelet hyperreactivity and to the microvascular complications in type I diabetes mellitus.
Conclusion
In diabetes a vicious cycle is set up in which vascular disease may lead to platelet damage, and altered platelet function may contribute to vascular disease. The loss of sensitivity to the normal restraints generated by the vascular endothelium is the major defect in platelet function. Platelet-leukocyte cross-talk plays a pivotal role in platelet activity and is a very sensitive analysis tool. Inflammation not only leads to activation of coagulation, but also coagulation affects inflammatory activity. As the alterations in platelet activation are partly dependent on the metabolic status of the patient, various treatment modalities for diabetes mellitus affect platelet function differently. With analysis of the platelet proteome it may become possible to recognise the proteins involved. This could lead to new therapeutic intervention concepts in dealing with diabetes.
